VKTX News and Press, Viking Therapeutics Inc. From 06/15/24

2024-06-15 09:31:00 ET The S&P 500 remains near record levels as the markets have been strong this year. Finding good stocks to buy in such a hot market can be challenging. But a couple of growth stocks with lots of potential, based on their price targets from Wall Street, are V...

2024-06-15 07:45:00 ET A business can look to be in solid shape but still not necessarily be a great investment overall. A good example of that is Viking Therapeutics (NASDAQ: VKTX) . The company has been doing a lot of things well lately, and there's a lot of hope and optimism arou...

2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...

2024-06-12 12:33:43 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...

2024-06-10 09:45:00 ET Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver disease and obesity, and, until recently, despite the...

2024-06-09 08:45:00 ET The biotech industry features many prominent companies that command plenty of attention on the market. And since the year started, few biotechs have made more noise than Viking Therapeutics (NASDAQ: VKTX) , a mid-cap drugmaker. Viking focuses on developing...

2024-06-07 11:15:07 ET Summary Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss. Viking stock has become more volatile due to competition from other ...

2024-06-06 07:45:00 ET Viking Therapeutics (NASDAQ: VKTX) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered a staggering 208% return on capital for shareholders in 2024. The reason? Investors ha...

2024-06-05 13:00:00 ET Summary The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Albertsons, Viking Therapeutics, Brandywine Realty Trust, platinum, and more are discussed in this edition. A number of veteran Seeking Alph...

2024-06-05 09:00:17 ET Summary Structure Therapeutics Inc.'s oral GLP-1 agonist, GSBR-1290, showed a 6.2% mean weight loss over 12 weeks, significantly outperforming placebo. Adverse events were high, with 89.2% experiencing nausea and 62.2% vomiting. The financial outlook is ...